Dose reduction and toxicity of lenalidomide-dexamethasone in multiple myeloma: A machine-learning prediction model.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
PMID: 37670612

Abstract

PURPOSE: Lenalidomide remains an effective drug for multiple myeloma, but it is often associated with adverse events and requires dose adjustments. The objective of this study was to propose a model for predicting whether a patient would require dose adjustment.

Authors

  • Iván Maray
    Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Cristina Álvarez-Asteinza
    Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Clara Luz Fernández-Laguna
    Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Lola Macía-Rivas
    Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Mónica Carbajales-Álvarez
    Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Ana Lozano-Blazquez
    Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain.

Keywords

External Resources

Popular Topics
Recent Journals